Recon: Gilead to buy Immunomedics for $21B; Trump signs international reference pricing order

• Trump unveils plan to slash drug costs tied to what's paid abroad (Politico) (NYTimes) (WSJ) (STAT)
• Trump Pressed for Plasma Therapy. Officials Worry, Is an Unvetted Vaccine Next? (NYTimes)
• Gilead Reaches Deal to Buy Immunomedics for $21 Billion (WSJ) (FT) (Reuters) (STAT)
• Merck to buy $1 bln stake in Seattle Genetics, co-develop cancer therapy (Reuters)
• Trump officials interfered with CDC reports on Covid-19 (Politico)
• US Employers Eye Cutting Wasteful Drugs Worth $6 Billion (Bloomberg)
• Kodak Deal Draws Review From Watchdog at Agency Involved in Planned Loan (WSJ)
• Pfizer and BioNTech announce plan to expand Covid-19 vaccine trial (STAT) (Reuters) (Press)
• Eli Lilly Arthritis Drug Helped Hospitalized Covid-19 Patients Recover Faster (WSJ) (Press)
• FDA rejects Mallinckrodt's kidney drug over risk-benefit doubts (Fierce) (Endpoints)
• Vaccine maker got $1 billion from taxpayers. Now it’s boosting drug prices (LA Times)

• WHO head urges rich nations to join vaccine scheme by Friday deadline (Reuters)
• Oxford and AstraZeneca resume coronavirus vaccine trial (FT) (Reuters)
• Regeneron's antibody drug added to UK Recovery trial of COVID treatments (Reuters) (BBC)
• Coronavirus: UK to test inhaled vaccines (BBC)
• Russia completes volunteer recruitment for COVID-19 vaccine trial: fund (Reuters)
• UAE announces emergency approval for use of COVID-19 vaccine (Reuters)
• Roche says two-thirds of Evrysdi patients had got rival treatments (Reuters)
• Novartis aims to expand Beovu use after safety fears hurt launch (Reuters)
• Canada's Pascal Biosciences partners with SoRSE to test cannabis-based cancer therapy (Reuters)

• Vaccine Makers Keep Safety Details Quiet, Alarming Scientists (NYTimes)
• Not enough Covid vaccine for all until 2024, says biggest producer (FT)
• Trump Loyalists Tried to Influence CDC Virus Reports (NYTimes)
• Early research from 23andMe strengthens link between blood types and Covid-19 (STAT)
• Gilead CEO: We’re studying new ways to treat coronavirus with remdesivir outside of the hospital (CNBC)
• As COVID-19 Vaccine Trials Move At Warp Speed, Recruiting Black Volunteers Takes Time (NPR)
• Valneva announces major COVID-19 vaccine partnership with UK government (PMLive)
• Coronavirus (COVID-19) Update: Daily Roundup September 11, 2020 (FDA)

• Neurocrine launches Parkinson's therapy as COVID-19 related disruptions ease (Reuters)
• Cancer Projects to Diversify Genetic Research Receive New Grants (NYTimes)
• PIC/S Interprets Checklist For Auditing Drug GMP Inspectorates (Pink Sheet)
• How much is a startup worth? For biotech companies, the answer is rarely public (STAT)
• US FDA Oncology Applications: Real-Time Review And Breakthrough Pathway Show Durable Appeal (Reuters)
• ICER criticizes cost of 8 targeted immune modulators for UC, recommending some deep discounts (Endpoints)
• Gilead’s CAR-T player Kite waves goodbye to research chief Peter Emtage as another top exec hits the exit (Endpoints)
• Arie Belldegrun and David Chang godfather the $110M launch of a new cell therapy player. And this one is also thinking big (Endpoints)
• Thanks to a $77.5M Series B, Escient moves into the clinic with the first of its sensory receptor candidates (Endpoints)
• Escape Bio nabs $73M as race with well-heeled Biogen and Denali heats up (Endpoints)
• Stronger Unapproved Stem-Cell Enforcement Accompanies FDA Center for Biologics’ Cell and Gene Therapy Advancement Efforts (IPQ)
• FDA grants Dupixent® (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis (Press)
• Novartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME) (Press)
• Novartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS) (Press)

• Abbott, Illumina, other medtechs shape guide conveying device risks to patients (MedtechDive)
• Fitbit to launch first ECG app in U.S., Europe next month (Fierce)
• MHRA’s Lee To Give UK Medtech Industry Greater Diagnostics Focus (MedtechInsight)

• Patent board delivers blow to University of California over its CRISPR invention claims (STAT) (Science)
• A Pennsylvania lawmaker wants to tie prescription drug prices to what Canada pays (STAT)